be9a8b34-4ecb-4542-8d30-4d5019fd1903
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.300
- E2F_TARGETS+0.200
- G2M_CHECKPOINT+0.200
- MITOTIC_SPINDLE+0.200
- SPERMATOGENESIS+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- ESTROGEN_RESPONSE_EARLY+0.100
- KRAS_SIGNALING_DN+0.100
- MYOGENESIS+0.100
- APICAL_JUNCTION+0.000
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- CHOLESTEROL_HOMEOSTASIS-0.400
- COMPLEMENT-0.400
- IL2_STAT5_SIGNALING-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- COAGULATION-0.300
- FATTY_ACID_METABOLISM-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013518 | — | cohortSQ1 | 0.884 |
| 2 | SRR22247242 | — | cohortSC | 0.862 |
| 3 | C3N-03886 | — | cohortMD1 | 0.855 |
| 4 | BS_4E1G7E3G | ATRT | — | 0.850 |
| 5 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.848 |
| 6 | BS_VAAHBH60 | EPN | Supratentorial EPN | 0.840 |
| 7 | BS_44A3ES23 | medulloblastoma | — | 0.839 |
| 8 | TCGA-46-6026-01A-11R-1820-07 | — | cohortSQ1 | 0.837 |
| 9 | a9e8922f-fd6c-412d-85f5-40f5ea9b5455 | — | — | 0.837 |
| 10 | TCGA-CR-7398-01A-11R-2016-07 | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |